Jason Lukas, MD
Hematology & Oncology · Seattle, WANPI 1427204262
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $18,955 of the $25,523 with a category attached, or 74.3%. E.r. Squibb & Sons, L.L.C. accounts for 97.8% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $14,893 and has fallen 98.6% since, to $206 in 2025.
Across 42 payments — averaging $607.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$25K
- Tempus AI, Inc$127
- GSK$105
- Johnson & Johnson$99
- Foundation Medicine, Inc.$60
- Gilead$42
- plus $123 from 5 others
Across 47 payments — averaging $2826.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$73K
- E.r. Squibb & Sons, L.L.C.$46K
- F. Hoffmann-la Roche AG$14K
What the payments were for
- Consulting fees$3,92015%
- Speaking & faculty fees$18,95574%
- Travel & lodging$1,6376%
- Food & beverage$8423%
- Education$1681%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 24 | $24,967 |
| Tempus AI, Inc | 4 | $127 |
| GSK | 3 | $105 |
| Johnson & Johnson | 1 | $99 |
| Foundation Medicine, Inc. | 2 | $60 |
| Gilead | 2 | $42 |
| Genentech, Inc. | 1 | $37 |
| Bayer | 2 | $29 |
| AstraZeneca | 1 | $23 |
| Merck | 1 | $18 |
| Genentech USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,523 in reported general payments places this provider in the 85th percentile of 349 hematology & oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bupropion XlBupropion Hcl | 26 | $281 |
| Dexamethasone | 11 | $238 |
| Prednisone | 12 | $111 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Seattle
- John PesandoSeattle$15.7M
- Jill JohnsenSeattle$991K
- Fengting YanSeattle$841K
- John PagelSeattle$725K
- Lawrence FongSeattle$546K
- Langdon MillerSeattle$457K
- Mazyar ShadmanSeattle$226K
- Catherine LeeSeattle$199K
- Celestia HiganoSeattle$164K
- Ryan CassadaySeattle$151K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.